Zydus and Bayer forms Joint Venture in india

Posted on 29/01/2011 by

[Bayer Press Release] [Cadila Press Release]

Bayer and Zydus cadila yesterday announced and signed to form Joint venture in India named Bayer Zydus Pharma.

Bayer Zydus Pharma will operate in key segments of the Indian pharma market with a focus on: women’s healthcare, diagnostic imaging, cardiovascular diseases, anti-diabetic treatments, and oncology. Bayer Zydus Pharma’s future product portfolio will not only include in-licensed and originator brands, but also patented pharmaceuticals from Bayer HealthCare’s pipeline. The combined portfolio will encompass among others such popular brands as Glucobay®, Xarelto®, Nexavar® and Yaz/Yasmin® from Bayer HealthCare as well as products currently marketed by Zydus Cadila such as Euglim® , Progynova® and Ultravist®.

Note: Yaz/Yasmin patent application rejected in pre grant opposition and Nexavar’s (sorafenib) patent validity is also challenged by Cipla.

Update (17/11/2011): Bayer to bring innovative products into India (link)

Advertisement

About Guna

Interested to learn things around me
This entry was posted in Daily interesting IP news and tagged , , , , . Bookmark the permalink.

One Response to Zydus and Bayer forms Joint Venture in india

  1. Pingback: MedBlits.com

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out / Change )

Twitter picture

You are commenting using your Twitter account. ( Log Out / Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out / Change )

Cancel

Connecting to %s